CSL Limited operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares CSL Limited with three other
miscellaneous service companies in Australasia:
Sirtex Medical Limited
sales of 232.49 million Australian Dollars [US$178.57 million]
of which 86%
Tempo Australia Limited
(81.37 million Australian Dollars [US$62.50 million]
(58.52 million Australian Dollars [US$44.95 million]
of which 100%
was Mesenchymal Precursor Cell).
CSL Limited reported sales of A$8.43 billion (US$6.47 billion)
June of 2016.
increase of 23.9%
versus 2015, when the company's sales were A$6.80 billion.
Sales at CSL Limited have increased during each of the previous five years
(and since 2011, sales have increased a total of 101%).